European Leukodystrophy Association   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Laxou France (1992)

Organization Overview

First Clinical Trial
2008
NCT01303146
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

European Leukodystrophy Association

Active Ingredients

Drugs in Phase 4 Trials (1)

pramipexole (mirapex) (1 trial)

Drugs in Phase 2 Trials (3)

aavrh.10cuarsa (1 trial)

arylsulfatase a (1 trial)

zinc dichloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Canavan Disease (Phase 2)

Deficiency Diseases (Phase 2)

Leukodystrophy, Metachromatic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 4